Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

A newly published study in the New England Journal of Medicine highlighted this week that Novo Nordisk’s (NVO) GLP-1 agonist ...

Additionally, Novo Nordisk's new trial suggests potential treatment for fatty liver disease, emphasizing ongoing medical ...

The world’s latest AI machine is powered by the success of two products: Nvidia’s chips and Novo Nordisk’s weight-loss drugs.

A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis ...

The U.S. Food and Drug Administration on Friday warned patients and health care professionals not to use compounded drugs, ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced promising results from the first part of its ESSENCE trial, showing that ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Novo Nordisk's semaglutide trial showed 62.9% of patients experienced resolution of symptoms with no worsening of scarring. "Novo Nordisk's Weight-Loss Drug Helps Improve Symptoms of Liver Disease, ...